Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Immenhausen
Clinical trial register · Germany

Clinical Trials in Immenhausen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5062 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:18 UTC
5062
Studies in scope
all four open statuses
2869
Recruiting now
open to new participants
983
Lead sponsors
across recruiting studies
Top sites
Berlin 1587 Hamburg 893 Essen 765 Dresden 714 Heidelberg 626
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca4 Bristol-Myers Squibb3 Hoffmann-La Roche3 Merck Sharp & Dohme LLC2 Revolution Medicines, Inc.2 Eli Lilly and Company2 Boehringer Ingelheim2 IHF GmbH - Institut für Herzinfarktforschung1 AbbVie1 ModernaTX, Inc.1 GlaxoSmithKline1 OncoC4, Inc.1 Regeneron Pharmaceuticals1 Nuvalent Inc.1 Uptake Medical Technology, Inc.1 Janssen Research & Development, LLC1 United Therapeutics1 Daiichi Sankyo1 Insmed Incorporated1 Pfizer1 Gilead Sciences1 Endeavor Biomedicines, Inc.1 Vicore Pharma AB1
Site location
Berlin1587 Hamburg893 Essen765 Dresden714 Heidelberg626 Cologne619 Leipzig513 München510 Hanover487 Tübingen454 Bonn422 Düsseldorf409 Munich398 Freiburg im Breisgau394 Erlangen374 Frankfurt369 Münster359 Frankfurt am Main343 Ulm343 Mainz336 Würzburg296 Aachen266 Augsburg248 Kiel234 Lübeck225 Show all 638
All 638 locations
Target enrolment
to

Trials with a site in Immenhausen

34 of 5062 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
80
Essen, Hanover, Immenhausen, Solingen
2026-02-10
Recruiting
Insmed Incorporated
Phase 3
344
Heidelberg, Immenhausen, Stuttgart, München, Bonn, Essen, Homburg, Dresden
2026-01-07
Recruiting
AbbVie
Phase 2
180
Immenhausen, Marburg, Berlin
2025-11-25
Recruiting
Pfizer
Phase 3
680
Heidelberg, Stuttgart, Hösbach, Frankfurt am Main, Giessen, Immenhausen, Kassel, Bonn
2025-09-29
Recruiting
GlaxoSmithKline
Phase 3
420
Karlsruhe, Löwenstein, Stuttgart, Augsburg, Chemnitz, Esslingen am Neckar, Heidelberg, Immenhausen
2025-08-11
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Berlin, Esslingen am Neckar, Großhansdorf, Immenhausen, Velbert
2025-07-17
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Gauting, München, Giesen, Immenhausen, Göttingen, Essen, Dresden, Lübeck
2025-05-06
Recruiting
AstraZeneca
Phase 3
990
Bendorf, Berlin, Haltern am See, Hanover, Immenhausen, Lübeck, Marburg, Rosenheim
2025-03-18
Active, closed
Vicore Pharma AB
Phase 2
378
Freiburg im Breisgau, Heidelberg, Tübingen, Frankfurt am Main, Immenhausen, Hanover, Essen, Berlin
2024-12-09
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
DrugTaladegib
Endeavor Biomedicines, Inc.
Phase 2
213
Giessen, Immenhausen, Hanover, Essen, Berlin, Leipzig
2024-11-15
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Immenhausen, Essen, Großhansdorf, Esslingen am Neckar, Giessen, Hamburg, Hemer, Neuss
2024-07-16
Recruiting
AstraZeneca
Phase 3
582
Berlin, Cologne, Erfurt, Frankfurt, Göttingen, Immenhausen, Kiel, Mainz
2024-04-29
Recruiting
BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation
NCT05717192Emphysema or Chronic Obstructive Pulmonary Disease
IHF GmbH - Institut für Herzinfarktforschung
Not applicable
224
Berlin, Bonn, Essen, Halle, Heidelberg, Hemer, Immenhausen, Langen
2024-04-24
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Berlin, Cologne, Dresden, Frankfurt am Main, Heidelberg, Immenhausen, Moers
2024-01-18
Active, closed
Bristol-Myers Squibb
Phase 3
190
Esslingen am Neckar, Würzburg, Oldenburg, Berlin, Cologne, Dresden, Gauting, Immenhausen
2023-12-21
Recruiting
United Therapeutics
Phase 3
698
Rosenheim, Hanover, Bad Berka, Coswig, Essen, Immenhausen, Löwenstein, München
2023-10-30
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Freiburg I. Breisgau, Wangen I. Allgaeu, Munich, Münnerstadt, Immenhausen, Stralsund, Essen, Cologne
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Freiburg I. Breisgau, Munich, Münnerstadt, Hamburg, Immenhausen, Marburg, Essen, Cologne
2023-09-14
Active, closed
Boehringer Ingelheim
Phase 2
268
Berlin, Essen, Frankfurt, Großhansdorf, Hanover, Immenhausen, Jena, Konstanz
2023-09-08
Active, closed
OncoC4, Inc.
Phase 3
630
Bogenhausen, Essen, Esslingen am Neckar, Immenhausen, Immenstädt, Muenchen-Gauting
2023-06-28
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Berlin, Cologne, Grosshandorf, Immenhausen, Würzburg
2022-11-11
Recruiting
ModernaTX, Inc.
Phase 1/2
361
Immenhausen
2022-09-01
Active, closed
AstraZeneca
Phase 3
341
Berlin, Chemnitz, Frankfurt A. Main, Gauting, Immenhausen, Löwenstein, München, Münster
2022-08-03
Active, closed
Daiichi Sankyo
Phase 3
586
Essen, Esslingen am Neckar, Frankfurt am Main, Gauting, Giessen, Großhansdorf, Heidelberg, Immenhausen
2022-07-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Heidelberg, Immenhausen, Hanover, Großhansdorf, Gera
2022-03-24
Active, closed
Eli Lilly and Company
Phase 3
152
Heidelberg, Löwenstein, Gauting, München, Immenhausen, Georgsmarienhütte, Hanover, Münster
2021-12-20
Active, closed
Hoffmann-La Roche
Phase 3
660
Bad Berka, Berlin, Chemnitz, Essen, Georgsmarienhütte, Großhansdorf, Halle, Immenhausen
2021-11-18
Active, closed
Gilead Sciences
Phase 3
603
Braunschweig, Esslingen am Neckar, Hamburg, Heilbronn, Immenhausen, Kassel, Lübeck, Mannheim
2021-11-17
Active, closed
Hoffmann-La Roche
Phase 3
1,000
Ulm, Regensburg, Lübeck, Essen, Freiburg im Breisgau, Gauting, Gera, Immenhausen
2019-02-28
Active, closed
Hoffmann-La Roche
Phase 3
257
Chemnitz, Georgsmarienhütte, Heidelberg, Immenhausen
2018-08-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Esslingen am Neckar, Immenhausen, Düsseldorf, Hemer, Rheine, Koblenz, Dresden, Leipzig
2018-04-24
Recruiting
Post-Market BTVA Registry
NCT03318406Emphysema or COPD
Uptake Medical Technology, Inc.
Observational
300
Bamberg, Berlin, Essen, Gauting, Halle, Heidelberg, Hemer, Immenhausen
2018-03-22
Active, closed
AstraZeneca
Phase 3
1,186
Berlin, Essen, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Immenhausen, Mainz
2017-06-01
Active, closed
Eli Lilly and Company
Phase 3
453
Berlin, Gera, Großhansdorf, Hamburg, Hanover, Heidelberg, Immenhausen, Nuremberg
2014-10-03
Rows per page Showing 1–34 of 34
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-germany/city/immenhausen

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,062 studies in total at the last sync on 10 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 34 of those studies with a site in Immenhausen.

How many clinical trials are recruiting in Immenhausen?

15 of the 34 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Immenhausen), 34 studies
PhaseStudiesRecruitingShare
Phase 324970.6%
Phase 26217.6%
Phase 1/2225.9%
Not applicable112.9%
Observational112.9%

Most active sponsors

Lead sponsors with the most studies (Immenhausen)
Lead sponsorStudiesRecruiting
AstraZeneca42
Bristol-Myers Squibb30
Hoffmann-La Roche30
Boehringer Ingelheim21
Eli Lilly and Company20
Merck Sharp & Dohme LLC20
Revolution Medicines, Inc.22
AbbVie11
Daiichi Sankyo10
Endeavor Biomedicines, Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.